Relay Therapeutics Inc (RLAY) FinancialsRLAYRelay Therapeutics Inc

Evaluating the bottom line, Relay Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25949.71%, while the net margin is -23916.29%. These profitability ratios, combined with a Return on Equity (ROE) of -36.77%, provide a clear picture of how effectively RLAY converts its operational activities into shareholder value.

In the context of the broader market, RLAY competes directly with industry leaders such as ADPT and ELVN. With a market capitalization of $4.35B, it holds a significant position in the sector. When comparing efficiency, RLAY's gross margin of 100.00% stands against ADPT's 71.23% and ELVN's N/A. Such benchmarking helps identify whether Relay Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Relay Therapeutics has shown a gross margin of 100% across recent quarters, indicating strong pricing power and cost management. However, it has reported significant net losses, with a net income of -83,707,000 USD in Q2 2026.